Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/142530
Full metadata record
DC FieldValueLanguage
dc.creatorSaavedra, A
dc.creatorRodrigues, E
dc.creatorCarvalho, D
dc.date.accessioned2022-08-01T11:22:31Z-
dc.date.available2022-08-01T11:22:31Z-
dc.date.issued2020
dc.identifier.issn0870-399X
dc.identifier.urihttps://hdl.handle.net/10216/142530-
dc.description.abstractIn about 28% of patients, dyslipidemia has a secondary cause. Many times, the treatment of these causes can lead to the total correction of dyslipidemia. We describe the case of a 50-year-old female patient with class II obesity and primary biliary cirrhosis, evaluated for mixed dyslipidemia with poor control (statins and fibrates were being administered) as well as abnormal liver tests. The investigation carried out revealed primary auto-immune hypothyroidism. After normalisation of thyroid function by treatment with levothyroxine, as well as suspending the administration of statins and fibrates, there was an improvement in the lipid profile, although hypercholesterolemia continued. During this time, the patient was diagnosed with diabetes and she re-commenced statin therapy (atorvastatin 10 mg), which resulted in a normal lipid profile being achieved. In this case, the authors set out to highlight the importance of excluding secondary causes of dyslipidemia - including hypothyroidism, and then go on to discuss particular aspects of statin therapy for liver disease.
dc.language.isopor
dc.publisherOrdem dos Médicos
dc.relation.ispartofActa Medica Portuguesa, vol.33(3), p. 204-207
dc.rightsopenAccess
dc.rights.urihttps://www.creativecommons.org/licenses/by-nc/4.0/
dc.subject.meshAtorvastatin / therapeutic use
dc.subject.meshAutoimmune Diseases / diagnosis
dc.subject.meshAutoimmune Diseases / drug therapy
dc.subject.meshCholestasis / complications
dc.subject.meshDiabetes Mellitus / diagnosis
dc.subject.meshDyslipidemias / drug therapy
dc.subject.meshDyslipidemias / etiology
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
dc.subject.meshHypothyroidism / complications
dc.subject.meshHypothyroidism / diagnosis
dc.subject.meshHypothyroidism / drug therapy
dc.subject.meshLiver Cirrhosis, Biliary / complications
dc.subject.meshMiddle Aged
dc.subject.meshObesity / complications
dc.subject.meshThyroxine / therapeutic use
dc.subject.meshWithholding Treatment
dc.titleDyslipidemia secondary to hypothyroidism and cholestasis
dc.typeArtigo em Revista Científica Nacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.20344/amp.9944
dc.relation.publisherversionhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9944
Appears in Collections:I3S - Artigo em Revista Científica Nacional

Files in This Item:
File Description SizeFormat 
10.20344-amp.9944.pdf308.86 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons